← Clinical Trials
Herpes Simplex Labialis Phase 3 Time-to-Event Analysis NCT00809809

Zinc for the Treatment of Herpes Simplex Labialis (HSL): Complete Statistical Analysis

The registry record describes a randomized comparison of zinc gluconate swabs with placebo for recurrent herpes simplex labialis. The posted primary results are median time to lesion resolution, with wide confidence intervals and no reported comparative test result.

Trial start: 2008-12  ·  Enrollment: 157  ·  Sponsor: Integrative Medicine Institute
Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.

1. Trial at a Glance

This page covers the registry results for Zinc for the Treatment of Herpes Simplex Labialis (HSL) (NCT00809809), a randomized phase 3 study. The primary outcome is Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or After 14 Days of Treatment, Whichever Comes First..

157
Enrollment
Phase 3
2
Arms
In the primary outcome
n/a
Effect
No re-analysis shown
n/a
95% CI
See limitations
FeatureRegistry value
ClinicalTrials.gov identifierNCT00809809
PhasePhase 3
ConditionHerpes Simplex Labialis
AllocationRandomized
Design modelParallel
MaskingQuadruple
Enrollment157
Arms in the primary outcome2
Lead sponsorIntegrative Medicine Institute
Results postedYes

2. Clinical Question

The clinical question concerns whether treatment with the zinc preparation recorded as Zicam or Zinc gluconate differs from placebo in time to resolution of recurrent herpes simplex labialis (HSL). The primary outcome follows participants from the date and time therapy began until the lesion resolved or the treatment period reached 14 days, whichever came first.

Population

Participants with recurrent HSL were included in the primary outcome description. The record notes exclusions and repeat enrollment: some participants were excluded, and for twelve participants who enrolled twice, only their first enrollment was included in the analysis.

Intervention

The active treatment is labeled Zicam (Ionic zinc) in the intervention listing. The arm description calls it oral swabs containing homeopathic Zinc gluconate. These are the registry’s descriptions of the zinc treatment.

Comparator

The comparator is placebo, listed as a drug intervention and described in the arm record as placebo. The trial was randomized, quadruple-masked, and parallel-group according to the registry record.

Primary question

The primary outcome is median days to resolution, assessed over a 14-day timeframe. The record reports an estimate and a 95% confidence interval for each arm, but does not report a comparative hazard ratio or a p-value.

The registry also lists a secondary outcome concerning the incidence, speed, and rate of healing for aborted cold sore lesions. The posted results described in the record do not give a numerical result for that secondary outcome. The central statistical question is therefore how to interpret the arm-specific median estimates and their uncertainty, while distinguishing those summaries from an estimated treatment contrast. The posted medians alone do not quantify the between-arm difference through a time-to-event model.

3. Trial Design

This was a Phase 3, randomized, quadruple-masked, parallel-group trial sponsored by the Integrative Medicine Institute. The registry lists an enrollment of 157 and status as completed. The recorded study start is 2008-12 and primary completion is 2009-09. Its official title describes a randomized, double-blind, placebo-controlled, multi-center trial; the masking field separately specifies quadruple masking.

The intervention listing names Zicam (Ionic zinc) and placebo. The arm descriptions identify the active treatment as oral swabs containing homeopathic Zinc gluconate and describe the control as placebo. The registry wording is not entirely uniform across these entries, so the zinc product is best identified using the labels recorded rather than assuming further details about formulation or use.

Random allocation is intended to make the treatment groups comparable on average, while masking is intended to limit influences from treatment knowledge on participants, study staff, or outcome assessment. Those are general design purposes; the registry record does not describe how allocation was generated or concealed, who specifically was included in the masking count, or whether masking was assessed.

The primary outcome compares time from therapy initiation until lesion resolution, subject to the 14-day endpoint window. Arm-level results list 61 participants for active treatment and 73 for placebo. These outcome denominators are not the same information as total trial enrollment, and the registry record does not provide a full participant flow accounting for the difference. The primary outcome population description notes exclusions for eligibility criteria and concomitant medications, repeat enrollment, and family enrollment. The detailed accounting is incomplete, so the exact disposition of every enrolled participant is not reported in the registry record.

The registry lists one secondary outcome about aborted cold sore lesions and two outcome measures, but the count of analyses is zero. A complete protocol, allocation details, analysis plan, sample-size justification, or interim-monitoring description is not reported in the registry record. The listed design features therefore establish the broad structure of the study, but not all operational or analytic decisions.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Subjects were excluded if they had HSL for more than one day

Overall Study

StageActive TreatmentPlacebo Treatment
STARTED7879
COMPLETED7577
NOT COMPLETED32

Analysis population for the primary outcome, as defined in the registry: 5 subjects met exclusion criteria and were excluded from analysis. 2 subjects used concomitant medications and were excluded from the final analysis. Twelve subjects with recurrent HSL enrolled twice, only the 1st enrollment was included in the analysis. 2 subjects had family enroll who were excluded from analysis. Analysis - 134 subjects.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

CharacteristicUnitActive TreatmentPlacebo TreatmentTotal
Participants analysed7879157
Age, Categorical: <=18 yearsParticipants000
Age, Categorical: Between 18 and 65 yearsParticipants7879157
Age, Categorical: >=65 yearsParticipants000
Age, Continuousyears42.6 (SD 11.8)43.8 (SD 12.5)43.1 (SD 12.0)
Sex: Female, Male: FemaleParticipants6062122
Sex: Female, Male: MaleParticipants181735
Region of Enrollment: United Statesparticipants7879157

6. Primary Endpoint

The registry lists the primary outcome as Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or After 14 Days of Treatment, Whichever Comes First., measured over 14 days.

ElementRegistry entry
Result typeMedian
Measure of spread95% Confidence Interval
UnitDays to resolution
Endpoint classificationTime-to-Event Analysis

The primary endpoint is median time to lesion resolution, expressed in days. The time origin is the date and time treatment began; follow-up ends when the lesion resolves or after 14 days of treatment, whichever comes first. The registry’s timeframe is 14 days. This endpoint captures how long resolution takes rather than simply whether a lesion is present at a single visit.

In general, time-to-event outcomes are useful when the timing of an event matters and participants may have different follow-up durations. Resolution is the event of interest in this trial. A median is the time by which half of the observed event-time distribution has experienced the event, subject to how the analysis handles participants who have not yet experienced it. The registry record does not describe the exact estimator or how censoring was handled, so that definition is a general interpretation rather than a confirmation of the trial’s calculation.

The posted active-treatment median is 8.0 days, with a 95% confidence interval from 0.0 to 16.0. The placebo median is 6.0 days, with a 95% confidence interval from 0.0 to 21.0. These estimates describe each arm separately. A comparative time-to-event analysis would ordinarily summarize the relative timing between groups, but a hazard ratio or other comparative estimate is not reported in the registry record.

The endpoint is bounded by the stated 14-day treatment period, but the reported confidence intervals extend beyond that timeframe. The record does not explain the estimation method or why the intervals have those limits. This makes it important to read the estimates as posted, without inferring a specific analytic procedure from the endpoint description alone.

7. Why No Re-analysis Is Shown

Reported as posted, not recalculated. Values missing or not estimable for a two-arm comparison (median time endpoint). A result is recalculated only when the posted data support a clean two-arm comparison, so no result is shown beyond what the sponsor posted.

8. Statistical Interpretation

Clinical Biostats interpretation

The posted outcome is a median time to resolution of 8.0 days for active treatment, with a 95% confidence interval of 0.0 to 16.0 days. For placebo, the median is 6.0 days, with a 95% confidence interval of 0.0 to 21.0 days. These are arm-specific summaries, not an estimate of the treatment effect expressed as a contrast between arms.

A confidence interval conveys uncertainty around an estimate under the assumptions of the method used. In general, a wider interval indicates less precision. Both intervals are broad, and their reported ranges overlap. Overlap does not by itself establish whether a formal comparison is statistically significant; that judgment depends on the comparison estimate and its uncertainty or a prespecified test. Neither a comparative hazard ratio nor a p-value is reported in the registry record.

The posted sample sizes for this outcome are 61 in the active-treatment arm and 73 in the placebo arm. The primary outcome description says that some participants were excluded from analysis and that repeat enrollments were handled by including only the first enrollment. Because the record does not provide a complete participant flow or explain the estimator, it is not possible to determine from these entries alone how each exclusion or any incomplete follow-up affected the medians.

The analysis listing contains no analyses, and the posted-results information does not include the sponsor’s hazard ratio. The record’s methods note indicates that time-to-event comparisons use sponsor-reported hazard ratios, but no such estimate is available in this record. The calculation pathway for a two-arm comparison is marked as unavailable or not estimable for this median-time endpoint. Accordingly, no recalculated comparison or inferential test should be read into the arm-level results.

The medians describe observed resolution timing in the analyzed groups as recorded; they do not establish that the groups differ. Nor do they show that a particular participant would experience the median time. The confidence intervals are important context: the reported values are estimates with uncertainty, not exact underlying times. Since no comparative estimate or test is posted, the statistical evidence for a difference cannot be assessed from the registry results.

The record’s total enrollment is 157, while the primary outcome arm counts are 61 and 73. These figures have different roles: enrollment is the trial-level count, and the arm figures are the outcome-specific counts. Without a complete disposition account, they should not be forced into a reconciliation. The registry’s exclusions and repeat-enrollment note provide some context, but do not report every reason for the difference.

Overall, the result supports a careful descriptive reading: the posted median is 8.0 days in active treatment and 6.0 days in placebo, with substantial uncertainty around each estimate. The data as posted do not provide the comparative time-to-event result needed to quantify how the arms differ statistically. No conclusion about benefit or lack of benefit follows from the descriptive medians alone.

9. Statistical Methods Explained

The primary outcome is a time-to-event measure. The event is lesion resolution, the clock begins at therapy initiation, and the specified observation period ends at resolution or after 14 days of treatment, whichever comes first. In general, time-to-event analysis accounts for both whether an event occurs and when it occurs. It can also accommodate participants whose event time is not observed during follow-up, if the analysis records them as censored. The registry record does not state whether or how censoring was handled in this analysis.

What does a median time represent?

In general, the median event time is the point at which the estimated event-time distribution reaches one half. It is a measure of the distribution’s middle, not an average and not a guarantee about an individual participant’s experience. The registry identifies the summary parameter as a median and gives the unit as days to resolution. The estimation method, including any survival-curve procedure, is not reported in the registry record.

The active-treatment median is 8.0 days, with a 95% confidence interval of 0.0 to 16.0. The placebo median is 6.0 days, with a 95% confidence interval of 0.0 to 21.0. In general, a confidence interval describes uncertainty in an estimated quantity under the statistical method’s assumptions. The intervals are broad relative to the point estimates. The record does not identify the method used to calculate them or explain why their upper limits extend beyond the 14-day timeframe.

Why is a median not a treatment contrast?

A median reported separately for each arm describes that arm’s event-time distribution. It does not directly estimate a relative treatment effect. In general, a time-to-event comparison may use a hazard ratio, which compares the instantaneous event rates between groups over follow-up under the model’s assumptions. A hazard ratio is distinct from a difference between medians, and its interpretation depends on the model and assumptions, including whether the relative rates are adequately represented by the model.

The registry’s methods note says that time-to-event results use sponsor-reported hazard ratios. No hazard ratio is reported in the registry record, and the analysis count is zero. The record also marks a two-arm comparison as unavailable or not estimable for the median-time endpoint. Consequently, the posted medians should not be converted into a claimed hazard ratio or a formal between-arm test. No new comparison can be derived from the given arm-level summaries alone.

What does uncertainty tell the reader?

In general, interval width reflects precision: narrower intervals indicate a more precise estimate, while wider intervals leave more uncertainty about plausible values under the method. Confidence intervals for separate arms are not the same thing as a confidence interval for the difference or relative effect between arms. Their overlap is not a substitute for a formal treatment comparison. The registry does not post the comparative estimate, its confidence interval, or a p-value, so the strength and precision of a comparative effect cannot be assessed from the posted endpoint numbers.

The stated endpoint window also matters. Resolution is observed up to the limit of 14 days, but the confidence intervals are reported as extending to 16.0 and 21.0 days. A time-to-event estimator can produce uncertainty limits that do not match a simple observed follow-up boundary, depending on the method and data structure. That is a general possibility, not an explanation confirmed for this trial. The estimation details are not reported in the registry record.

How should sample-size planning be read?

In general, a sample-size calculation is a planning exercise: it estimates how many participants might be needed under specified assumptions to detect a chosen effect with a selected significance level and power. The assumptions described for the planning illustration are a two-sided significance level of 0.05, equal allocation, a normal approximation, and an effect defined as a stated fraction of the observed effect. For time-to-event outcomes, the planning description refers to total events. These assumptions describe an illustration, not necessarily the trial’s original design.

The planning illustration is based on the observed effect, and such calculations should not be read as observed power. No numerical planning estimates are reported in the registry record. The trial’s own sample-size justification, target effect, power calculation, and design assumptions are not reported in the registry record. The registry enrollment of 157 is not, by itself, evidence that the study had adequate or inadequate statistical power.

What can the listed analysis status establish?

The registry lists zero analyses. This means the record does not supply a registered analysis result beyond the posted outcome entries described. The analytic population, handling of censoring, model specification, covariate adjustment, and approach to missing data are not reported in the registry record. Those omissions limit the ability to assess whether the posted arm summaries represent a prespecified analysis or how sensitive they might be to analytic choices.

For these reasons, the most defensible statistical reading is descriptive. The medians and their confidence intervals convey the posted arm-level summaries and their uncertainty. They do not replace a comparative time-to-event estimate, and the registry record does not contain enough analytic detail to reconstruct one.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one secondary outcome, concerning the incidence, speed, and rate of healing for aborted cold sore lesions. It also lists two outcome measures and zero analyses. A multiplicity adjustment or a prespecified hierarchy for primary and secondary testing is not reported in the registry record. In general, when several outcomes or comparisons are tested, the chance of at least one false-positive result can increase; statistical plans may address this through adjustment or other prespecified approaches. Whether any such approach was used in this trial is not reported in the registry record.

The primary outcome description notes that 5 subjects met exclusion criteria and were excluded from analysis, and that 2 subjects used concomitant medications and were excluded from the final analysis. It also states that twelve subjects with recurrent HSL enrolled twice and only the first enrollment was included. The record further mentions 2 subjects had family enroll who were excluded, but the wording does not fully clarify the circumstances or the resulting analysis disposition.

These entries provide some information about exclusions, but not a complete accounting of all enrolled participants, missing outcome data, withdrawals, or reasons for non-inclusion. The exact analysis population definition, whether the analysis followed randomized assignment, and any imputation or other missing-data method are not reported in the registry record. In general, excluding participants after randomization can affect comparability if the reasons for exclusion are related to treatment or outcome; the available record does not allow that possibility to be evaluated.

Because the analysis count is zero and no analysis plan is described, it is also not possible to determine from the registry record whether the outcome analysis was prespecified, how repeated observations were handled beyond the stated first-enrollment rule, or how missing follow-up was treated. The outcome-specific arm counts are reported, but a participant-flow diagram or complete reconciliation with total enrollment is not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

ArmParticipants with serious adverse eventsParticipants at riskPercentage
Active Treatment0780.0%
Placebo Treatment0790.0%

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

ArmParticipants affected of at risk
Active Treatment0 of 78
Placebo Treatment0 of 79
Do not overextend the safety comparison. Serious-adverse-event counts are safety observations, not efficacy outcomes, and should not be combined with the primary result into a single benefit-risk number.

The serious adverse event entries list 78 participants at risk in the active-treatment group and 79 at risk in the placebo group. The number affected by serious adverse events is 0 in each group. These figures mean that the registry reports no serious adverse events in the recorded at-risk groups; they do not establish that the risk of such events is absent.

In general, an observed count of zero is still compatible with uncertainty about the underlying event rate, especially when the number observed is limited. It should be interpreted as a description of events recorded during the study, not as proof of safety or a comparison showing equivalent safety. The record does not provide a comparative safety estimate or confidence interval.

The adverse-event entries also list zero participants affected by other adverse events in both groups. The deaths field is not populated with a numeric value, so deaths are not reported in the registry record. The types of serious adverse events are not listed. The at-risk counts differ from the primary outcome arm counts, and the record does not explain the relationship between these safety populations and the efficacy analysis population. These safety figures therefore describe the recorded events and denominators only, without supporting broader conclusions.

12. What the Result Does, and Does Not, Mean

The posted primary results describe median time to lesion resolution in each treatment group. The active-treatment median is 8.0 days, with a 95% confidence interval of 0.0 to 16.0. The placebo median is 6.0 days, with a 95% confidence interval of 0.0 to 21.0. These estimates are uncertain summaries of the analyzed groups, not exact predictions for individuals.

The registry record does not report a hazard ratio, a comparative confidence interval, or a p-value for the primary outcome. It also indicates that a two-arm comparison is unavailable or not estimable for this median-time endpoint. Thus the posted results do not quantify the treatment contrast or establish whether the observed arm summaries differ beyond what could arise from sampling uncertainty.

These data do not demonstrate that the zinc treatment works, and they do not demonstrate that it does not work. A descriptive difference between two arm medians is not enough to draw either conclusion. A comparative analysis, together with a clear account of its assumptions and uncertainty, would be needed to evaluate the magnitude and precision of a treatment effect. Such a result is not reported in the registry record.

The endpoint applies to recurrent HSL and uses a treatment window of 14 days. The primary outcome description identifies exclusions and a rule for repeat enrollment, but does not provide a full analysis-population account. The results therefore pertain to the participants included in the posted outcome analysis, whose full selection and follow-up details are not reported in the registry record.

The safety entries record zero serious adverse events among the listed at-risk participants in each group. That is a useful description of the events recorded, but it is not proof that serious harms cannot occur, nor does it establish equivalence between treatments. Overall, the record offers arm-level timing summaries and safety counts while leaving the comparative efficacy analysis and several details needed for a fuller statistical assessment unreported.

13. Why This Trial Matters Statistically

This trial is statistically instructive because it illustrates the difference between an outcome summary and a treatment comparison. A median time for each arm can describe the timing observed in each group, but it does not itself estimate the relative effect of treatment. The distinction is especially important for time-to-event outcomes, where a comparative model may account for event timing and incomplete follow-up in ways that separate arm medians cannot show.

The uncertainty intervals are essential context. The reported active-treatment and placebo medians have 95% confidence intervals of 0.0 to 16.0 and 0.0 to 21.0, respectively. These broad intervals make clear that the point estimates should not be read as precise fixed values. Yet intervals for separate groups do not replace an interval for a direct contrast. A reader should avoid using visual overlap alone as a significance test.

The record also highlights the importance of transparent analysis reporting. It includes a primary endpoint description and arm summaries but lists zero analyses, and does not report a comparative hazard ratio or p-value. Important details about censoring, missing outcomes, exclusions, and the analysis population are incomplete. Without those details, the summaries can be described, but the analytic pathway and robustness of the result cannot be fully evaluated.

Finally, enrollment and outcome denominators need to be kept distinct. The registry reports total enrollment of 157 and separate arm counts for the primary outcome. It also documents exclusions and repeat enrollment, but not a complete participant flow. In general, clear participant accounting helps readers understand which randomized participants contributed to each outcome and why. The record’s partial accounting is a limitation for interpreting both the estimates and their generalizability.

14. Limitations

The primary outcome results are limited to arm-specific medians and confidence intervals. A comparative hazard ratio, comparative confidence interval, and p-value are not reported in the registry record. The record marks the two-arm comparison as unavailable or not estimable for this median-time endpoint, so the posted data do not support a direct statistical assessment of the treatment contrast.

The method used to estimate the medians and confidence intervals is not reported in the registry record. Details of censoring, event-time modeling, handling of participants without observed resolution, and the assumptions behind the confidence limits are also not reported. The upper confidence limits extend beyond the stated 14-day timeframe, but the record does not explain this feature.

The primary outcome population description notes exclusions for exclusion criteria and concomitant medication use, repeat enrollment, and family enrollment. It does not provide a complete participant flow or a full reconciliation of the outcome arm counts with trial enrollment. The missing-data approach and the final analysis-population definition are not reported in the registry record. This limits assessment of selection and attrition effects.

The registry lists a secondary outcome but provides no secondary result in the record summarized. It lists zero analyses, and multiplicity handling is not reported. The protocol, statistical analysis plan, sample-size justification, allocation procedure, and details of masking implementation are not reported in the registry record. The active-treatment labels also vary between Zicam (Ionic zinc) and oral swabs containing homeopathic Zinc gluconate; further formulation details are not reported.

Safety reporting is limited to the at-risk counts and recorded event counts. Serious adverse event terms are not listed, and deaths are not reported in the registry record. These limitations do not negate the posted descriptive findings, but they constrain the conclusions that can be drawn from them.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

Continue through the Clinical Biostats statistical pathway

Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.

18. Record Summary

The registry record describes a completed Phase 3 randomized, quadruple-masked, parallel-group trial sponsored by the Integrative Medicine Institute, with enrollment of 157. It compares a zinc preparation, described as Zicam (Ionic zinc) and as oral swabs containing homeopathic Zinc gluconate, with placebo for recurrent herpes simplex labialis.

The primary endpoint is median days to lesion resolution, measured from treatment initiation until resolution or after 14 days, whichever comes first. The active-treatment median is 8.0 days (95% confidence interval, 0.0 to 16.0); the placebo median is 6.0 days (95% confidence interval, 0.0 to 21.0). No comparative hazard ratio or p-value is reported in the registry record.

The outcome description notes exclusions and repeat enrollment, but a complete participant flow, detailed analysis methods, and missing-data approach are not reported. Serious adverse events are recorded for 0 participants in each listed at-risk group. The posted results support descriptive interpretation but do not establish a comparative treatment effect.

Need an analysis like this for your own study?

Our team supports biostatistics, statistical programming and pharmacometric analyses. Send us a request and we will reply by email.

Request an analysis
Clinical Biostats